Skip to main content

Table 1 Clinical significance of MDSCs in lung cancer

From: Myeloid-derived suppressor cells—new and exciting players in lung cancer

Refs.Phenotype (MDSCs)Tumor tissue (TT)/
peripheral blood (PB)
NSCLC/SCLCNo. of patientsImplications
[14]CD11b+CD14CD15+CD33+PBAdvanced NSCLC41Decreased in the advanced-stage patients who had clinical benefit (PR or SD) and in the early-stage patients after removal of tumor.
[15]CD11b+CD14+S100A9+PBAdvanced NSCLC24Poor chemotherapy response and short PFS
[16]CD16lowCD11b+CD14HLA-DRCD15+CD33+PBAdvanced NSCLC185Significantly increased compared to healthy controls
[17]CD14+HLA-DR−/lowPBNSCLC60Negatively correlated with PFS
[18]CD14+HLA-DR−/lowPBSCLC42Independent biomarker for poor prognosis
[19]B7-H3+CD14+HLA-DR−/lowPBNSCLC111Decreased RFS
[20]CD11b+CD14HLA-DRCD33+CD15+ ILT3highPBStage IV
105Decreased OS
[21]linCD14CD11b+ CD39+/CD73+PMN-MDSCs
linCD14+CD11b+ CD39+/CD73+M-MDSCs
PBNSCLC24Decreased with chemotherapy cycles in SD and PR groups, increased in PD group.
[22]LinCD14 + CD15 + CD11b + CD33 + HLA-DRPBNSCLC110Independent prognostic marker for decreased PFS and OS.
[23]LinCD14HLA-DRPBNSCLC46After three cycles, bevacizumab-based chemotherapy significantly reduced the level of LinCD14HLA-DR cells.
[24]Lox-1+ PMN-MDSCsPBNSCLC34Patients with a higher ratio of Tregs to Lox-1+PMN-MDSCs in the blood after the 1st nivolumab had better PFS.
[25]LinCD33 + CD14 + CD15 HLA-DRPBMetastatic NSCLC61Decreased OS in anti-PD-1 treatment.
[26]SSClowLinHLA-DR−/LOWCD33+ CD13+CD11b+CD15+CD14PBstage IIIB or IV NSCLC53PMN-MDSCs (≥6 cell/μl) showed a significantly improved survival in anti-PD-1 treatment.
[27]CD33+CD11b+CD14 PMN-MDSCs CD33+CD11b+CD14+HLA-DR−/low M-MDSCsPBNSCLC7Both subtypes decreased after SBRT treatment.
[28]CD11b+HLA-DR−/lowCD14CD15+ PMN-MDSCs
CCR5+HLA-DR−/lowCD11b+CD14+CD15 M-MDSCs
TT and PBResectable NSCLC42TT PMN-MDSCs displayed higher PD-L1 expression levels than the same cells in the PB.
Significant correlations between lower total PMN-MDSCs and CCR5+ M-MDSCs frequencies in the peripheral blood and improved RFS.
  1. PR partial response, SD stable disease, PD progressive disease, PFS progress free survival, RFS recurrence-free survival, OS overall survival, SBRT stereotactic body radiotherapy